Genetic test evaluation: Information needs of clinicians, policy makers, and the public

Wylie Burke, David Atkins, Marta Gwinn, Alan Guttmacher, James Haddow, Joseph Lau, Glenn Palomaki, Nancy Press, Carolyn (Sue) Richards, Louise Wideroff, Georgia L. Wiesner, Muin Khoury

    Research output: Contribution to journalArticle

    148 Citations (Scopus)

    Abstract

    Growing knowledge about gene-disease associations will lead to new opportunities for genetic testing. Many experts predict that genetic testing will become increasingly important as a guide to prevention, clinical management, and drug treatment based on genetic susceptibilities. As part of a Human Genetic Epidemiology workshop convened by the Centers for Disease Control and Prevention, a group of experts evaluated the evidence needed when considering the appropriate use of new genetic tests. Because new tests are likely to vary in their predictive value, their potential to direct prevention or treatment efforts, and their personal and social consequences, the task of determining appropriate use will require careful consideration of a variety of factors, including the analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications of the test. Standardized formats are needed to summarize what is known and not known about new genetic tests with respect to each of these features. Following criteria for the objective assessment of test properties, reports should be structured to enable policy makers, clinicians, and the public to identify the available evidence, so that uncertainties can be taken into account when considering test use and planning future research.

    Original languageEnglish (US)
    Pages (from-to)311-318
    Number of pages8
    JournalAmerican Journal of Epidemiology
    Volume156
    Issue number4
    DOIs
    StatePublished - Aug 15 2002

    Fingerprint

    Genetic Testing
    Administrative Personnel
    Molecular Epidemiology
    Medical Genetics
    Genetic Predisposition to Disease
    Centers for Disease Control and Prevention (U.S.)
    Uncertainty
    Education
    Therapeutics
    Pharmaceutical Preparations
    Genes

    Keywords

    • Factor V
    • Genetic markers
    • Genetic predisposition to disease
    • Genetic screening
    • Genetics
    • Phenylketonurias

    ASJC Scopus subject areas

    • Epidemiology

    Cite this

    Burke, W., Atkins, D., Gwinn, M., Guttmacher, A., Haddow, J., Lau, J., ... Khoury, M. (2002). Genetic test evaluation: Information needs of clinicians, policy makers, and the public. American Journal of Epidemiology, 156(4), 311-318. https://doi.org/10.1093/aje/kwf055

    Genetic test evaluation : Information needs of clinicians, policy makers, and the public. / Burke, Wylie; Atkins, David; Gwinn, Marta; Guttmacher, Alan; Haddow, James; Lau, Joseph; Palomaki, Glenn; Press, Nancy; Richards, Carolyn (Sue); Wideroff, Louise; Wiesner, Georgia L.; Khoury, Muin.

    In: American Journal of Epidemiology, Vol. 156, No. 4, 15.08.2002, p. 311-318.

    Research output: Contribution to journalArticle

    Burke, W, Atkins, D, Gwinn, M, Guttmacher, A, Haddow, J, Lau, J, Palomaki, G, Press, N, Richards, CS, Wideroff, L, Wiesner, GL & Khoury, M 2002, 'Genetic test evaluation: Information needs of clinicians, policy makers, and the public', American Journal of Epidemiology, vol. 156, no. 4, pp. 311-318. https://doi.org/10.1093/aje/kwf055
    Burke, Wylie ; Atkins, David ; Gwinn, Marta ; Guttmacher, Alan ; Haddow, James ; Lau, Joseph ; Palomaki, Glenn ; Press, Nancy ; Richards, Carolyn (Sue) ; Wideroff, Louise ; Wiesner, Georgia L. ; Khoury, Muin. / Genetic test evaluation : Information needs of clinicians, policy makers, and the public. In: American Journal of Epidemiology. 2002 ; Vol. 156, No. 4. pp. 311-318.
    @article{5cb463ed604f42be821bab2db094b83b,
    title = "Genetic test evaluation: Information needs of clinicians, policy makers, and the public",
    abstract = "Growing knowledge about gene-disease associations will lead to new opportunities for genetic testing. Many experts predict that genetic testing will become increasingly important as a guide to prevention, clinical management, and drug treatment based on genetic susceptibilities. As part of a Human Genetic Epidemiology workshop convened by the Centers for Disease Control and Prevention, a group of experts evaluated the evidence needed when considering the appropriate use of new genetic tests. Because new tests are likely to vary in their predictive value, their potential to direct prevention or treatment efforts, and their personal and social consequences, the task of determining appropriate use will require careful consideration of a variety of factors, including the analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications of the test. Standardized formats are needed to summarize what is known and not known about new genetic tests with respect to each of these features. Following criteria for the objective assessment of test properties, reports should be structured to enable policy makers, clinicians, and the public to identify the available evidence, so that uncertainties can be taken into account when considering test use and planning future research.",
    keywords = "Factor V, Genetic markers, Genetic predisposition to disease, Genetic screening, Genetics, Phenylketonurias",
    author = "Wylie Burke and David Atkins and Marta Gwinn and Alan Guttmacher and James Haddow and Joseph Lau and Glenn Palomaki and Nancy Press and Richards, {Carolyn (Sue)} and Louise Wideroff and Wiesner, {Georgia L.} and Muin Khoury",
    year = "2002",
    month = "8",
    day = "15",
    doi = "10.1093/aje/kwf055",
    language = "English (US)",
    volume = "156",
    pages = "311--318",
    journal = "American Journal of Epidemiology",
    issn = "0002-9262",
    publisher = "Oxford University Press",
    number = "4",

    }

    TY - JOUR

    T1 - Genetic test evaluation

    T2 - Information needs of clinicians, policy makers, and the public

    AU - Burke, Wylie

    AU - Atkins, David

    AU - Gwinn, Marta

    AU - Guttmacher, Alan

    AU - Haddow, James

    AU - Lau, Joseph

    AU - Palomaki, Glenn

    AU - Press, Nancy

    AU - Richards, Carolyn (Sue)

    AU - Wideroff, Louise

    AU - Wiesner, Georgia L.

    AU - Khoury, Muin

    PY - 2002/8/15

    Y1 - 2002/8/15

    N2 - Growing knowledge about gene-disease associations will lead to new opportunities for genetic testing. Many experts predict that genetic testing will become increasingly important as a guide to prevention, clinical management, and drug treatment based on genetic susceptibilities. As part of a Human Genetic Epidemiology workshop convened by the Centers for Disease Control and Prevention, a group of experts evaluated the evidence needed when considering the appropriate use of new genetic tests. Because new tests are likely to vary in their predictive value, their potential to direct prevention or treatment efforts, and their personal and social consequences, the task of determining appropriate use will require careful consideration of a variety of factors, including the analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications of the test. Standardized formats are needed to summarize what is known and not known about new genetic tests with respect to each of these features. Following criteria for the objective assessment of test properties, reports should be structured to enable policy makers, clinicians, and the public to identify the available evidence, so that uncertainties can be taken into account when considering test use and planning future research.

    AB - Growing knowledge about gene-disease associations will lead to new opportunities for genetic testing. Many experts predict that genetic testing will become increasingly important as a guide to prevention, clinical management, and drug treatment based on genetic susceptibilities. As part of a Human Genetic Epidemiology workshop convened by the Centers for Disease Control and Prevention, a group of experts evaluated the evidence needed when considering the appropriate use of new genetic tests. Because new tests are likely to vary in their predictive value, their potential to direct prevention or treatment efforts, and their personal and social consequences, the task of determining appropriate use will require careful consideration of a variety of factors, including the analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications of the test. Standardized formats are needed to summarize what is known and not known about new genetic tests with respect to each of these features. Following criteria for the objective assessment of test properties, reports should be structured to enable policy makers, clinicians, and the public to identify the available evidence, so that uncertainties can be taken into account when considering test use and planning future research.

    KW - Factor V

    KW - Genetic markers

    KW - Genetic predisposition to disease

    KW - Genetic screening

    KW - Genetics

    KW - Phenylketonurias

    UR - http://www.scopus.com/inward/record.url?scp=0037103382&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0037103382&partnerID=8YFLogxK

    U2 - 10.1093/aje/kwf055

    DO - 10.1093/aje/kwf055

    M3 - Article

    C2 - 12181100

    AN - SCOPUS:0037103382

    VL - 156

    SP - 311

    EP - 318

    JO - American Journal of Epidemiology

    JF - American Journal of Epidemiology

    SN - 0002-9262

    IS - 4

    ER -